'lizbeth
06-22-2012, 12:19 PM
http://www.cancer.ucla.edu/index.aspx?page=1280
HER2+ metastatic breast cancer, a particularly aggressive form of the disease, currently accounts for about one in every five breast cancer diagnoses. In this moving profile, HER2+ metastatic breast cancer survivor Dr. Kathy Bennett, who was diagnosed with the disease in 2008, and UCLA Jonsson Comprehensive Cancer Center researcher and Herceptin pioneer Dr. Dennis Slamon, discuss how clinical trials turn survivors and scientists into colleagues, uniting them in the search for a cure. From AACR News.
Watch the video (http://www.cancer.ucla.edu/index.aspx?page=1280).
HER2+ metastatic breast cancer, a particularly aggressive form of the disease, currently accounts for about one in every five breast cancer diagnoses. In this moving profile, HER2+ metastatic breast cancer survivor Dr. Kathy Bennett, who was diagnosed with the disease in 2008, and UCLA Jonsson Comprehensive Cancer Center researcher and Herceptin pioneer Dr. Dennis Slamon, discuss how clinical trials turn survivors and scientists into colleagues, uniting them in the search for a cure. From AACR News.
Watch the video (http://www.cancer.ucla.edu/index.aspx?page=1280).